Jasper Therapeutics (JSPR) Retained Earnings (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Retained Earnings of $320.8 million for Q4 2025, up 6.04% year-over-year from $302.5 million in Q4 2024, and up 204.3% quarter-over-quarter from -$307.6 million in Q3 2025.
Jasper Therapeutics (JSPR) Retained Earnings (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $320.8 million for Q4 2025.
- In Q4 2025, Retained Earnings rose 6.04% year-over-year to $320.8 million; the TTM figure through Dec 2025 stood at $320.8 million (up 6.04% YoY), while the FY2025 annual figure was $320.8 million, up 6.04% from the prior year.
- Retained Earnings for Q4 2025 stood at $320.8 million, up from -$307.6 million in the prior quarter.
- The five-year high for Retained Earnings was $320.8 million in Q4 2025, with the low at -$307.6 million in Q3 2025.
- The 5-year median for Retained Earnings is -$42.6 million (2021), against an average of -$19.0 million.
- The sharpest annual moves came in 2021 and 2022: Retained Earnings soared 2417.28% in 2021, then slumped 1455.02% in 2022.
- Jasper Therapeutics' Retained Earnings stood at $137.0 million in 2021, then rose by 3.04% to $141.1 million in 2022, then soared by 75.76% to $248.0 million in 2023, then climbed by 21.97% to $302.5 million in 2024, then gained by 6.04% to $320.8 million in 2025.
- Business Quant data shows JSPR's Retained Earnings at $320.8 million in Q4 2025, -$307.6 million in Q3 2025, and -$288.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | 322.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 320.82 Mn |
| Sep 30, 2025 | -307.60 Mn |
| Jun 30, 2025 | -288.83 Mn |
| Mar 31, 2025 | -262.10 Mn |
| Dec 31, 2024 | 302.54 Mn |
| Sep 30, 2024 | -216.55 Mn |
| Jun 30, 2024 | -197.90 Mn |
| Mar 31, 2024 | -183.33 Mn |
| Dec 31, 2023 | 248.04 Mn |
| Sep 30, 2023 | -153.02 Mn |
| Jun 30, 2023 | -135.48 Mn |
| Mar 31, 2023 | -119.40 Mn |
| Dec 31, 2022 | 141.12 Mn |
| Sep 30, 2022 | 139.49 Mn |
| Jun 30, 2022 | -80.06 Mn |
| Mar 31, 2022 | 137.76 Mn |
| Dec 31, 2021 | 136.96 Mn |
| Sep 30, 2021 | 136.99 Mn |
| Jun 30, 2021 | -5.15 Mn |
| Mar 31, 2021 | 6.58 Mn |